Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, scheduled for September 9-11, 2024. The company's President and CEO, Dinesh V. Patel, Ph.D., will engage in a fireside chat on Tuesday, September 10 at 1:30 P.M. ET.
The fireside chat will be accessible via webcast, providing an opportunity for investors and interested parties to gain insights into Protagonist's developments and strategies. Additionally, the company will be available for one-on-one meetings during the conference, offering a more personalized interaction for attendees.
This participation underscores Protagonist's commitment to engaging with the investment community and sharing updates on its progress in the biotechnology sector.
Protagonist Therapeutics (NASDAQ:PTGX) ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright che si terrà a New York, NY, dal 9 all'11 settembre 2024. Il presidente e CEO dell'azienda, Dinesh V. Patel, Ph.D., parteciperà a una chat informale il martedì 10 settembre alle 13:30 ET.
La chat sarà accessibile tramite webcast, offrendo l'opportunità agli investitori e alle parti interessate di ottenere informazioni sui progressi e le strategie di Protagonist. Inoltre, l'azienda sarà disponibile per incontri individuali durante la conferenza, fornendo un'interazione più personalizzata per i partecipanti.
Questa partecipazione sottolinea l'impegno di Protagonist nel coinvolgere la comunità degli investitori e nel condividere aggiornamenti sui suoi progressi nel settore biotecnologico.
Protagonist Therapeutics (NASDAQ:PTGX) ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright en Nueva York, NY, programada para el 9 al 11 de septiembre de 2024. El presidente y CEO de la compañía, Dinesh V. Patel, Ph.D., participará en una charla informal el martes 10 de septiembre a la 1:30 P.M. ET.
La charla estará accesible a través de un webcast, brindando una oportunidad para que los inversores y partes interesadas obtengan información sobre los desarrollos y estrategias de Protagonist. Además, la compañía estará disponible para reuniones individuales durante la conferencia, ofreciendo una interacción más personalizada para los asistentes.
Esta participación subraya el compromiso de Protagonist de involucrar a la comunidad inversora y compartir actualizaciones sobre su progreso en el sector biotecnológico.
Protagonist Therapeutics (NASDAQ:PTGX)는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열릴 예정입니다. 회사의 회장 겸 CEO인 Dinesh V. Patel, Ph.D.는 9월 10일 화요일 오후 1시 30분 ET에 비공식 대화에 참여할 것입니다.
이 비공식 대화는 웹캐스트를 통해 접속 가능하며, 투자자와 이해관계자들이 Protagonist의 발전 및 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다. 또한, 회사는 컨퍼런스 기간 동안 개별 미팅을 제공하여 참석자와의 보다 개인화된 상호작용을 제공합니다.
이 참여는 Protagonist가 투자 커뮤니티와 적극 소통하고 생명공학 분야의 진행 상황에 대한 업데이트를 공유하려는 의지를 강조합니다.
Protagonist Therapeutics (NASDAQ:PTGX) a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright à New York, NY, prévue du 9 au 11 septembre 2024. Le président et CEO de l'entreprise, Dinesh V. Patel, Ph.D., participera à une discussion informelle le mardi 10 septembre à 13h30 ET.
Cette discussion sera accessible par webcast, offrant aux investisseurs et aux parties intéressées l'occasion d'obtenir des informations sur les développements et les stratégies de Protagonist. De plus, l'entreprise sera disponible pour des réunions individuelles pendant la conférence, offrant une interaction plus personnalisée pour les participants.
Cette participation souligne l'engagement de Protagonist à dialoguer avec la communauté des investisseurs et à partager des mises à jour sur ses avancées dans le secteur de la biotechnologie.
Protagonist Therapeutics (NASDAQ:PTGX) hat seine Teilnahme an der 26. Jahrestagung der globalen Investitionen H.C. Wainwright in New York, NY, die vom 9. bis 11. September 2024 stattfinden soll, bekannt gegeben. Der Präsident und CEO des Unternehmens, Dinesh V. Patel, Ph.D., wird am Dienstag, den 10. September um 13:30 Uhr ET an einem informellen Gespräch teilnehmen.
Das Gespräch wird via Webcast zugänglich sein, was Investoren und Interessierten die Möglichkeit bietet, Einblicke in die Entwicklungen und Strategien von Protagonist zu gewinnen. Darüber hinaus wird das Unternehmen während der Konferenz für Einzelgespräche zur Verfügung stehen, um eine persönlichere Interaktion mit den Teilnehmern zu bieten.
Diese Teilnahme unterstreicht das Engagement von Protagonist, mit der Investorengemeinde in Kontakt zu treten und Updates über seine Fortschritte im Biotechnologiesektor zu teilen.
- None.
- None.
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024
Format: Fireside Chat
Day/Time: Tuesday, September 10 at 1:30 P.M. ET
Webcast: https://journey.ct.events/view/6728cec4-cfc2-42c8-bb71-746abcedbd33
If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of REVIVE has also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
View the original press release on accesswire.com
FAQ
When is Protagonist Therapeutics (PTGX) participating in the H.C. Wainwright Global Investment Conference?
Who will represent Protagonist Therapeutics (PTGX) at the H.C. Wainwright conference?
How can investors access Protagonist Therapeutics' (PTGX) presentation at the H.C. Wainwright conference?
Will Protagonist Therapeutics (PTGX) be available for individual meetings during the conference?
